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Microcephaly with Simplified Gyration,
Epilepsy, and Infantile Diabetes Linked
to Inappropriate Apoptosis of Neural Progenitors
Cathryn J. Poulton,1 Rachel Schot,1 Sima Kheradmand Kia,1 Marta Jones,3 Frans W. Verheijen,1
Hanka Venselaar,4 Marie-Claire Y. de Wit,2 Esther de Graaff,5 Aida M. Bertoli-Avella,1
and Grazia M.S. Mancini1,*
We describe a syndrome of primary microcephaly with simplified gyral pattern in combination with severe infantile epileptic enceph-
alopathy and early-onset permanent diabetes in two unrelated consanguineous families with at least three affected children. Linkage
analysis revealed a region on chromosome 18 with a significant LOD score of 4.3. In this area, two homozygous nonconserved missense
mutations in immediate early response 3 interacting protein 1 (IER3IP1) were found in patients from both families. IER3IP1 is highly
expressed in the fetal brain cortex and fetal pancreas and is thought to be involved in endoplasmic reticulum stress response. We
reported one of these families previously in a paper on Wolcott-Rallison syndrome (WRS). WRS is characterized by increased apoptotic
cell death as part of an uncontrolled unfolded protein response. Increased apoptosis has been shown to be a cause of microcephaly
in animal models. An autopsy specimen from one patient showed increased apoptosis in the cerebral cortex and pancreas beta cells,
implicating premature cell death as the pathogenetic mechanism. Both patient fibroblasts and control fibroblasts treated with siRNA
specific for IER3IP1 showed an increased susceptibility to apoptotic cell death under stress conditions in comparison to controls. This
directly implicates IER3IP1 in the regulation of cell survival. Identification of IER3IP1mutations sheds light on the mechanisms of brain
development and on the pathogenesis of infantile epilepsy and early-onset permanent diabetes.Introduction
Microcephaly is defined as small brain size detected by
a head circumference more than 2.5 standard deviations
(SD) below the mean for age and sex. Microcephaly can
be either primary, i.e., congenital and present at birth, or
progressive, i.e., caused by a decrease of the head circum-
ference growth rate, which was normal until birth. The
incidence of primary microcephaly ranges from 1 in
10,000 (consanguineous population) to 1 in 30,000 (non-
consanguineous population).1 Primary microcephaly is
considered to be caused by a brain developmental defect,
and at present, the most widely accepted classification of
primary microcephaly is Barkovich’s et al. classification,
which is based on brain MRI imaging and genetic knowl-
edge.2 The classification includes microcephaly with
a normal or a simplified cortex (MSG [MIM 603802]),
with a thickened cortex (microlissencephaly, presumed
to result from a neuronal migration disorder), or with pol-
ymicrogyria (presumed to be caused by a defect of cortical
organization) and other structural malformations. MSG is
presumed to be derived from abnormal neuronal and glial
proliferation or apoptosis.1 Mutations in at least seven
genes (ASPM [MIM 605481], MCPH1 [MIM 607117],
CDK5RAP2 [MIM 608201] , CEP152 [MIM 613529], CENPJ
[MIM 609279], WDR62 [MIM 613583] and STIL [MIM
181590])3 have been found that are causative for congen-
ital primary microcephaly with normal or simplified gyra-1Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlan
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isolated microcephaly. These patients have near-normal
motor development with speech delay and moderately
compromised cognition. In a recent review, microcephaly
with simplified gyral pattern represented the largest group
of patients with primary microcephaly, and almost all of
these had near-normal function, with only mildly delayed
milestones, and none had epilepsy.4
In contrast, primary microcephaly also occurs in
syndromes with additional features. In such cases, patients
have a poorer neurological function, with severe cognitive
and motor impairment and epilepsy as common symp-
toms. For this group of patients, mutations in at least
four genes (SLC25A19 [MIM 606521],2 ATR [MIM
609215],3 ARFGEF2 [MIM 605371],5 RAB3GAP1 [MIM
602536]5) have been identified.
Darvish et al. recently reviewed genetic causes of micro-
cephaly in 112 Iranian families and came to the conclusion
that the genetic cause is even more heterogeneous than
previously thought.6
A common function of many known microcephaly
genes (both isolated and with additional features) in-
cludes a role in microtubule and centrosomal organiza-
tion, regulating mitosis, which is postulated to occur via
a disruption in the balance of symmetrical and asym-
metrical division of neural progenitors in the prolifera-
tive layer of the developing cortex; i.e., the ventricular
and subventricular zone. This is dependent on correctds; 2Department of Paediatric Neurology, Erasmus MC, Rotterdam, The
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centrosome and microtubule orientation to achieve the
correct cleavage plane.7
Despite this common theme, studies in animal models
have shown that abnormal control of apoptosis can also
be a pathogenic mechanism; therefore, it has been
proposed as a cause of human MSG but has thus far not
been demonstrated in patients.2 Apoptosis is an important
regulatory mechanism of brain development, specifically
related to the size of the forebrain.8 Apoptosis is under
complex control, which results in activation of the caspase
cascade and ultimately cell death.
The assumption that regulation of apoptosis is necessary
for normal brain development has been demonstrated in
Mosþ/ mice haploinsufficient for Magoh, the exon junc-
tion complex component, which controls brain size by
regulating neural stem cell division. Mutant mice show
a microcephaly due to both an increase in neuronal
apoptosis and a depletion of the intermediate neuron
progenitor population.9 Additionally, mice deficient in
the RhoGTPase Rac1 produce a phenotype similar to
primary microcephaly and also demonstrate an increase
in apoptosis in the forebrain.10
In contrast, a reduction of apoptosis leads to increased
brain size in caspase 9 knockout mice.11 This further
supports the hypothesis that a specific level of apoptosis
is needed for normal brain development.
In some human disorders, deletion or duplications at the
same locus can alternatively cause either micro- or macro-
cephaly, demonstrating a dosage effect and suggesting
a primary regulation of brain size, hence of neural prolifer-
ation, at that same locus.12
In some cases apoptosis is a response to stress condi-
tions; for example, if an excess of unfolded proteins accu-
mulate in the endoplasmic reticulum (ER stress). In such
cases a cascade of events, collectively called an unfolded
protein response (UPR), provides suppression of protein
translation. If this UPR mechanism fails, apoptotic
cascades are triggered, leading to cell death.13
Infantile-onset permanentdiabetes (permanentneonatal
diabetes, PND [MIM 606176]) has an incidence of approxi-
mately 1/260 000.14 Unlike juvenile- and adult-onset
diabetes, it is not found to have an autoimmune cause.
Instead, the main mechanism is inappropriate apoptosis
of Langerhans beta-islet cells, which are unable to cope
with ER stress. This has been described in Wolcott-Rallison
Syndrome (WRS [MIM 22980]), the most common cause
of PND in patients with consanguineous parents, which
is caused by a mutation in the eukaryotic translation
initiation factor 2-alpha kinase 3 gene, EIF2AK3.15 Patients
exhibit a combination of PND associated with multiple
epiphyseal dysplasia and variable additional clinical fea-
tures, including psychomotor retardation, hepatic dysfunc-
tion, and MSG.16
We have ascertained three patients from two consan-
guineous families with a striking overlapping phenotype.
The affected children presented at an early age with the
combination of MSG on MRI as well as infantile epileptic266 The American Journal of Human Genetics 89, 265–276, August 1encephalopathy and infantile diabetes, resembling WRS,
and EIF2AK3mutations had been excluded.We have previ-
ously described one of these patients as representing a
phenocopy of WRS, with unknown cause.16 We then per-
formed linkage analysis and identified overlapping areas
of homozygosity by genomic SNP array analysis of the
index patients. We hypothesized that these patients are
suffering from a distinct genetic, presumably autosomal-
recessive, syndrome, and the results in this paper confirm
this hypothesis.Material and Methods
Patient Material and Study Approval
All the family members and patient caretakers provided written
informed consent for participation in the study, and the genetic
analysis was approved by the Erasmus Medical Centre research
ethics committee.Pathology Study
A complete autopsy was performed by M.J. on the male sibling
of patient 2 (index patient 3, individual II:3 in Figure 1A, lower
pedigree) shortly after his death at 26 months. The material was
fixed in 10% formalin, and samples were analyzed on 5-mm-thick
hematoxylin and eosin-stained sections of paraffin-embedded
tissue. Immunohistochemistry for insulin was used in the pancre-
atic histological sections.
The brain was fixed in 10% buffered-formalin and sectioned.
Samples from frontal, parietal, temporal, and occipital lobes; deep
nuclei; cerebellum; brain stem; and spinal cord were submitted
for histological evaluation. This was performed on 5-mm-thick
hematoxylin and eosin-stained sections of paraffin-embedded
brain tissue. Myelin stain (Luxol Fast Blue) was also used.SNP Array, Homozygosity Mapping, and Linkage
Analysis
DNA samples from the index patients, parents, and unaffected
siblings were hybridized to the arrays according to the Affymetrix
standard protocol for the GeneChip Mapping 250K NspI Array.
Genotype data analysis was performed with Affymetrix GeneChip
Genotyping analysis software (GTYPE) using the BRLMM algo-
rithm. The obtained .CEL and .CHP files were used for homozy-
gosity mapping in CNAG version 3.017,18 and linkage analysis
with Allegro in easyLINKAGE v2.1.19Sequencing Analysis
Amplification reactions were performed in a total volume of 20 ml,
containing 13 PCR buffer with Mg (Roche), 200 mMof each dNTP,
1 mM forward primer, 1 mM reverse primer, 0.1 units Fast Start Taq
DNA polymerase (Roche), and 25 ng genomic DNA. PCR condi-
tions were as follows: 50 96C, 10 cycles of 3000 96C, 3000 68C
(1C/cycle), 6000 72C, followed by 25 cycles of 3000 96C, 3000
58C, 6000 72C, and a final extension for 50 72C.
PCR reactions were purified with ExoSAP-IT (USB). Direct
sequencing of both strands was performed with Big Dye Termi-
nator chemistry (version 3.1; Applied Biosystems). DNA fragment
analysis was performed with capillary electrophoresis on an ABI
3130 Genetic Analyzer (Applied Biosystems) with the software
package Seqscape (Applied Biosystems, version 2.1).2, 2011
Figure 1. Family Pedigrees and Linkage Data
(A) Simplified genealogical trees of two unrelated families with MSG, epilepsy, and PND. Filled symbols represent affected patients. A
double line represents consanguinity. An asterisk represents subjects analyzed by SNP arrays and included in the linkage analysis.
The results of microsatellite marker analysis confirming homozygosity are also shown. The shaded areas represent the alleles containing
the mutation, and the box represents the area found by linkage analysis.
(B) Output from easyLINKAGE showing an HLOD score of 4.3 for the region on chromosome 18q.Microsatelite Markers Analysis
Amplification reactions were performed in a total volume of
20 ml, containing 13 PCR buffer with Mg (Roche), 200 mM ofThe Americeach dNTP, 1 mM forward primer, 1 mM reverse primer, 0.1 units
Fast Start Taq DNA polymerase (Roche), and 25 ng genomic
DNA. PCR conditions were as follows: 50 96C, 35 cycles ofan Journal of Human Genetics 89, 265–276, August 12, 2011 267
3000 96C, 3000 58C, 6000 72C, and a final extension for 50
72C.
PCR products were diluted and pooled in panels and loaded on
an ABI 3130 genetic analyzer with LIZ 500 Size Standard (Applied
Biosystems) in formamide. Data were analyzed with Gene Mapper
version 2.1 software (Applied Biosystems).Cell Culture and Apoptosis
Fibroblast Culture, RNA Isolation, cDNA Synthesis
Fibroblasts, obtained from the certified Cell Repository of the
department of Clinical Genetics, ErasmusMC, were routinely
tested for mycoplasma and were cultured in 175 cm2 culture
flasks in Dulbecco’s modified Eagle medium (DMEM, Lonza Bio-
whittaker) until 80% confluence. Total RNA was extracted with
Trizol reagent (GIBCO BRL Life Technologies,) and purified with
QIAGEN RNeasy mini columns (QIAGEN) according to the manu-
facturers’ protocols.
Reverse transcriptase was performed on 1 mg RNA in a total
volume of 20 ml with the use of the iScript cDNA Synthesis Kit
(BioRad) according to the manufacturer’s instructions.
Apoptosis Studies
Susceptibility-to-apoptosis studies were performed with the use of
cultured skin fibroblasts from the index patient of family 1,
a patient with confirmed Wolcott-Rallison syndrome bearing an
EIF2AK3 mutation,15 and five healthy control cell lines. Suscepti-
bility to apoptosis of cultured skin fibroblasts was measured by
fluorescent staining of active caspases with the use of the Flica
(Fluorescent-Labeled Inhibitor of Caspases) Apoptosis Multi-
Caspase Detection Kit (Immunochemistry Technologies), which
makes use of an inhibitor sequence of active caspases, according
to the manufacturer’s instructions. Fluorescent cells were scored
by two blinded investigators before and after stress induction by
24 hr serum deprivation, then an additional 24 hr exposure to
5 mM dithiothreitol (DTT), as a percentage of apoptotic fibro-
blasts. The experiment was repeated three times, each time per-
formed in triplicate. Necrosis versus apoptosis was tested by vital
staining exclusion with propidium iodide.Silencing Experiments: RNA Interference
Predesigned siRNA pools targeting human IER3IP1 (L-018948-01)
(MIM 609382) and nontarget control pools (D-001810-10-20)
were purchased from Dharmacon and used to knock down
IER3IP1 in fibroblasts. siRNA was delivered to the fibroblasts via
silentFECT Lipid Reagent (BioRad).
Silencing was confirmed at 24, 48, and 72 hr by RT-qPCR
(primers listed in Table S2 available online). Apoptosis was
induced after 24 hr of serum deprivation, followed by the addition
of 1.25mMDTT for 24 hr; apoptosis was detected and percentages
calculated with the use of the Flica Apoptosis Detection Kit as
described above.Quantitative PCR
RT-qPCRwas carried out using a KAPA SYBRH FAST qPCRKit (Kapa
Biosystems) in the CFX96 Real-Time system (BioRad). Thermal
cycling conditions were as follows: a denaturing step (95C for
3 min), followed by 35 cycles of denaturing (95C for 5’’), anneal-
ing, and extension (60C for 30’’). Fluorescence detection and data
analysis were performed by BioRad CFXManager 2.0. Experiments
were performed in triplicate with the use of UBE2D2 (Entrez
GeneID 7322 [MIM 602962]) as a reference for gene expression
normalization.20268 The American Journal of Human Genetics 89, 265–276, August 1Induction by TNF-a
Fibroblasts were cultured as described above to 80% confluency.
To study the induction of IER3 (MIM 602996) and IER3IP1 expres-
sion by TNF-a, the cultures were exposed to two different condi-
tions. The first was standard culture medium (no induction with
TNF-a); the second was induction with 10 ng/ml TNF-a for 3 hr.
After induction, RNA was isolated with the Trizol LS protocol
and RT-qPCR was performed for IER3 and IER3IP1 (primers listed
in Table S2).Results
Patient Description
Family 1
The index patient 1 (individual II:1 in Figure 1A, upper
panel) was a male infant born to consanguineous parents
(fifth-degree relatives; second cousins) of Moroccan origin
(Figure 1A, top panel). The parents also have two healthy
daughters and a healthy son. The patient was born after
a normal pregnancy, and at birth his head circumference
measured 2.5 SD below the mean. At 2 months of age he
presented with microcephaly greater than 3 SD below the
mean, developmental delay, hypotonia, epilepsy, obesity,
presumed hypogonadism, and infantile diabetes. At
2 months of age, the seizures were a combination of focal
seizures with secondary generalization and generalized
seizures. Electroencephalographs (EEG) showed high-
voltage asymmetric multifocal activity with abnormal
background progressing into burst suppression on sleep
EEG at 4 months and hypsarrythmia at 7 months. The
MRI showed a simplified gyral pattern of the cerebral cortex
and delayed myelination, but no overt cerebellar abnor-
mality (Figures 2A–2C). Additionalmetabolic and infection
screening, including a muscle biopsy, was negative. ARX
sequencing was normal. The diabetes and epilepsy were
difficult to control despite treatment with clonazepam,
vigabatrin, and sodium valproate. Patient 1 died at the age
of 18 months of a lower respiratory tract infection compli-
cated by therapy-resistant epilepsy and diabetes. A post-
mortem exam was declined by the family. His clinical
history has been reported by de Wit et al.16
Family 2
Index patient 2 (individual II:1 in Figure 1A, lower panel)
was the fourth affected child (there were also two similarly
affected sons and one affected daughter) from a pre-
sumedly consanguineous family in Argentina (Figure 1A,
lower panel). He was born at term gestation after a normal
pregnancy. Infantile diabetes and microcephaly, with
a brain size greater then 3 SD below the mean, were noted
at birth. MRI performed at 2months showedmicrocephaly
with a simplified gyral pattern (Figure 2). The seizures were
generalized tonic-clonic and myoclonic in type. One EEG
was performed at 2 years of age, which showed hypsarryth-
mia. After multiple hospital admissions with seizures and
poor diabetic control, patient 2 died at 27 months from
a lower respiratory tract infection complicated by epilepsy
and diabetes. In the family, three more siblings died of2, 2011
Figure 2. Patient Brain MRIs
(A–C) MRIs from patient 1 performed at 1 year of age. (A) T1-weighted image showing a simplified gyral pattern and increased intracra-
nial space with near-normal ventricular size. (B and C) T2-weighted coronal and axial view showing equal involvement of parietal lobes,
normal cerebellum, and basal ganglia with delayed myelination.
(D–F) Low-resolution MRIs from patient 2 at approximately 7 months of age. (D) Sagittal T1-weighted view showing a thin but present
corpus callosum and normal brain stem. (E) T1-weighted coronal view through the hippocampus showing simplified gyration and
hippocampal hypoplasia. (F) T2- weighted view, demonstrating the simplified gyral pattern and normal ventricular size.a similar disorder (reported asWest syndrome and infantile
diabetes), but medical records are not available.
Pathology Findings
Postmortemmacroscopic examination (performed after his
death at 26 months) of one similarly affected brother of
patient 2 from the Argentinian family (index patient 3,
individual II:3 in Figure1A, lowerpanel) confirmedextreme
microcephaly (weight 175 g) in comparison to an age-
matched control (970 g) and a simplified gyral pattern
throughout the cortex, with the temporal tips and interhe-
misperic parietal lobes showing extreme simplification
(Figures 3A–3D). The cerebellum, although relatively large
compared to the cortex, was also small (weight: 59 g; age-
matched control weight: 125 g). Microscopy revealed
a reduced number of neurons in the brain cortex, mainly
of layers 1 and 4; hypomyelination; and remarkable
apoptosis. Many picnotic dead cells were also observed in
the inferior olivary nucleus and in the cerebellum, and
the pancreas showed few and small islets with few
insulin-positive beta cells (Figures 3E–3G).
Molecular Analysis
The 250K SNP array data from the index patients
(probands), unaffected siblings, and parents were analyzedThe Americfor loss of heterozygosity (LOH) regions with the use of
CNAG, and the pedigrees were subsequently used in
easyLINKAGE.19 In both families, multiple areas of
apparent LOH larger than 1 Mb were observed in the
probands, suggesting homozygosity, which is compatible
with the reported consanguinity. We observed one LOH
region on chromosome 18 overlapping between patients
fromthe two families.We thenperformeda linkage analysis
on the SNP array data and found a significant LOD score of
4.3 linked to the same region on chromosome 18q, span-
ning a 10 Mb region and containing 43 genes (NCBI
build 36.3). The region was confirmed as homozygous in
the affected individuals andheterozygous in the unaffected
siblings bymicrosatellitemarkers (Figure 1A and Figure S1).
The genes in the linkage area were prioritized for
sequencing with the use of available expression data
from the GEO profile. In total, 12 genes were found to be
expressed in both the brain and the pancreas, and these
were all sequenced (Table S1). In both affected individuals
from the two pedigrees, a homozygous variation in
the immediate early response-3 interacting protein-1
(IER3IP1) was found. In index patient 1, a homozygous
missense change, c.62T>G (NM_016097.3), was found in
exon 1, causing a change in amino acid at position 21
from valine to glycine (p.Val21Gly). In index patient 2,an Journal of Human Genetics 89, 265–276, August 12, 2011 269
Figure 3. Brain Macroscopy and Histopathology
(A and B) Macroscopic view in real proportions of normal age-
matched brain (upper specimen) compared with index patient 3
postmortem brain (lower specimen); note the extreme micro-
cephaly and simplified gyration looking almost lissencephalic in
its medial surface.
(C and D) Macroscopic photographs of patient 3 brain, showing
shallow and insufficient-in-number sulci over the whole brain
surface, but more apparent in the temporal and parietal lobes.
Note that photos in (C) and (D) are not in scale with those in
(A) and (B).
(E–J)Histopathology. (E)Histopathology of normal cerebral frontal
cortex (age-matched to patient 3). (F) Patient 3 histopathology of
270 The American Journal of Human Genetics 89, 265–276, August 1a homozygous missense change, c.233T>C, was found in
exon 3. This causes a change in amino acid at position 78
from leucine to proline (p.Leu78Pro) (Figure 4A). The
parents in both families were confirmed to be heterozygous
for the changes, whereas the nonaffected siblings
were confirmed to be heterozygous or had no changes.
Unfortunately, no DNA of index patient 3 was available.
Neither of these changes were annotated in dbSNP 132 or
the 1000 Genome database, nor were they found in 300
ethnically matched control chromosomes, indicating in
each case an allele frequency lower than 0.3%.
No change predicted to be pathogenic was observed in
any of the other genes in the linkage area in the affected
subjects.In Silico IER3IP1 Function Prediction
and Mutation Effect
IER3IP1 encodes a small polypeptide protein of about
10 kDa.21 Protein-localization studies of IER3IP1 and the
yeast homolog Yos1p localize the protein to the ER and
Golgi and suggest its involvement in the control of COP-
II vesicle budding21,22. The protein sequence predicts one
N-terminal hydrophobic domain possibly including a
signal peptide sequence,23 a hydrophilic glycine-rich
domain (G-patch), putatively interacting with RNA, and
a C-terminal second hydrophobic transmembrane domain
(Figure 4A). The Signal P 3.0 server23 predicts a hydro-
phobic domain, including a signal peptide that is required
for targeting the peptide to the ER. The p.Val21Gly change
is located in this first domain and introduces a new glycine
just before the G-patch. Signal P 3.0 suggests that this
mutation is very close to a putative peptide cleavage
site, possibly interfering with the cleavage of the signal
sequence.23 Preliminary data show that IER3IP1 is unde-
tectable in fibroblasts from patient 1 (Figure S5). The
p.Leu78Pro change is located in the second transmem-
brane domain. Through the use of Project HOPE and
tools for predictions of amino acid changes on protein
structure, both mutations are predicted to cause a change
in protein structure and to be within a hydrophobic/trans-
membrane domain.24,25 The p.Leu78Pro change is pre-
dicted to be within an alpha helix and to have severe
effects on the structure of the protein (Figure S4).24,25 In
silico analysis of the p.Val21Gly change by the Grantham
Matrix Score,26 Polyphen-2,27 SIFT,28 SNAP,29 and Pmut30
programs predicted a pathogenic/nonneutral effect (see
Table S3). The p.Leu78Pro change was predicted to be
pathogenic/nonneutral by the Grantham Matrix Score,26
Polyphen-2,27 SNAP,29 and Pmut30 programs (see Table S3).the cerebral cortex showing numerous apoptotic neurons (arrows)
and some apoptotic glial cells (H&E 3 20). (G) Cerebellar folia:
Purkinje neurons are apoptotic (arrows) and internal granule cell
layer is diminished (H&E3 20). (H)Nearly all neurons and the infe-
rior olivary nuclei are apoptotic. (I and J) Patient 3 pancreas stained
for insulin (J), showing depletion of insulin-producing islet cells in
comparison to a normal pancreas (I).
2, 2011
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Figure 4. IER3IP1 Sequence and Expression in Developing Brain
(A) Schematic representation of human IER3IP1 showing the sequence, the predicted protein domains, and the location of the
p.Val21Gly and p.Leu78Pro mutations. Cross-species conservation of IER3IP1 in the areas of the mutations is shown at the bottom
of the diagram. Both of the predicted amino acid changes are in a highly conserved area of the gene and in the hydrophobic/transmem-
brane domains, and they are depicted in red.
(B) Expression of Ier3ip1 at E14.5 days in the whole-mouse embryo (left); zoomed in, in the right panel is the mouse brain, with arrows
pointing to increased expression in the ventricular and subventricular zone at the site of neurogenesis.24Both mutations are in a highly conserved area among
vertebrates (Figure 4A). Although very little has been pub-
lished about IER3IP1, a search in several in silico expres-
sion databases (GEO Profiles, GenePaint, Allen Brain Altlas,
MGI, EMBL-EBI) brought additional information about itsThe Americputative function. The mouse ortholog Ier3ip1 shows a
high level of expression during early gestation (embryonic
day 9.5 [E9.5] and E11.5, compared to E13.5), which corre-
sponds to the period of proliferation of neural progenitors.
In the developing mouse at E14.5, there is high expressionan Journal of Human Genetics 89, 265–276, August 12, 2011 271
Figure 5. Susceptibility of Cultured Fibroblasts to Apoptosis and TNF-a Stimulation
(A) Patient cells are more susceptible to apoptosis, similar to cells from a knownWRS patient, when treated with 5 mMDTT, in compar-
ison to five control cell lines (p% 0.001, unpaired t test, SPSS version 17.0). Values represent a mean of three experiments5 SEM.
(B) IER3IP1 expression levels in control fibroblasts are decreased approximately 10-fold after the addition of IER3IP1 siRNA, as compared
to control siRNA (p% 0.001, unpaired t test, SPSS version 17.0) (left panel). Control fibroblasts treated with IER3IP1 siRNA also demon-
strate a significantly increased susceptibility to apoptosis (p% 0.001, unpaired t test, SPSS version 17.0) when treated with 1.25mMDTT
in comparison to control fibroblasts (right panel). Values represent a mean of three experiments5 SEM.
(C) IER3mRNA levels are increased approximately 10-fold in patient and control cells after the addition of TNF-a (left panel) (p< 0.0001,
unpaired t test, SPSS version 17.0). IER3IP1 levels are increased approximately 1.5-fold in patient and control fibroblast cell lines after the
addition of TNF-a (p < 0.001, unpaired t test, SPSS version 17.0) (right panel). Stars represent a significant p < 0.01 difference.of Ier3ip1 in the cortex in the ventricular/subventricular
zone at the site of neurogenesis31 (Figure 4B).
Expression in the embryonic pancreas peaks at E12.5
and lowers at E13.5 and E14.5 (GEO Profiles, GenePaint).
There also appears to be expression in the lungs and the
kidneys. The IER3IP1 mRNA is putatively translated into
the endoplasmic reticulum, suggesting that it functions as
a membrane-bound protein (EMBL-EBI database). In the
adult mouse brain, its expression is low and essentially
limited to the cerebellum, hippocampal area, midbrain,
and thalamus, with low, albeit detectable, expression in
the cortex (Allen Brain Atlas). There is also additional
evidence that IER3IP1 is downregulated by miR-34a.32
Once transactivated by p53, this miRNA is known to272 The American Journal of Human Genetics 89, 265–276, August 1promoteapoptosis.32 Thesedata suggest aputative function
for IER3IP1 in protecting neural progenitors in the prolifer-
ative zone of the embryonic forebrain from apoptosis.
In Vitro Apoptosis Tests
As a next step, we tested the general tendency of cultured
fibroblasts to undergo apoptosis through the use of a
test for active caspases after induction of stress by dithio-
threitol.33
Fibroblasts from index patient 1 with an IER3IP1 muta-
tion showed a significantly increased tendency to undergo
apoptosis after treatment with DTT in comparison to
control cells (p % 0.001, unpaired t test, SPSS version
17.0) (Figure 5A). The rate of apoptosis was similar to that2, 2011
of the cells of a patient with confirmed Wolcott-Rallison
syndrome.16 However, considering that the p.Val21Gly
missense mutation could synthesize an abnormal protein,
increased apoptosis could be the result of putative ER stress
induced by a less-functional IER3IP1 protein accumulating
in the ER and not linked to a specific function of IER3IP1
in protecting the cells from apoptosis. We therefore tested
the susceptibility to stress induced by DTT after silencing
of IER3IP1 in control fibroblasts by specific siRNA. RT-
qPCR of the IER3IP1 transcript showed efficient downregu-
lation; i.e., diminished predicted IER3IP1 synthesis
(Figure 5B, left panel) In cells in which IER3IP1 had been
knocked down, a significant increase (p% 0.001, unpaired
t test, SPSS version 17.0) in apoptosis was observed after
stress induced by 1.25 mM DTT, in comparison to the
same cell line treated with control siRNA (Figure 5B, right
panel). The DTT concentration in these experiments was
lower because the siRNA treatment made cells more
susceptible to apoptosis (also seen in control experiments).
No difference in the level of apoptosis was observed in the
absence of stress or when the cells were only exposed to
serum deprivation (data not shown).
These results demonstrate that IER3IP1 is needed in vitro
to protect cells from the consequences of stress induced
by denaturing agents such as DTT.
TNF-a Experiments
In the gene annotation databases, IER3IP1 is considered as
a putative interactor of IER3, early immediate response-3,
regulating acute stress response and cell death through
the TNF-a pathway,34 but any evidence for the human
protein is lacking. In control fibroblasts, we found that
expression of IER3 mRNA was approximately 10-fold
higher after induction with TNF-a in comparison to stan-
dard culture conditions (p < 0.0001, unpaired t test, SPSS
version 17.0) (Figure 5C). To test whether IER3 and IER3IP1
are similarly regulated, we looked at the expression of
IER3IP1 after the addition of TNF-a. There was an approx-
imate 1.5-fold increase in expression of IER3IP1 mRNA
after induction with TNF-a in both index patient 1 and
control fibroblasts (p < 0.001, unpaired t test, SPSS version
17.0), suggesting that IER3IP1 is under similar control as
IER3 (Figure 5C).
Discussion
We have described a syndrome consisting of MSG, PND,
severely apoptotic brain, and infantile epileptic encepha-
lopathy, in patients from two separate families, associated
with mutations in the IER3IP1.
Collectively, the linkage and IER3IP1 sequence data,
together with the expression pattern during brain develop-
ment and its involvement in regulation of apoptosis
in vitro, indicate that the mutations observed in our
patients are causally related to their disease.
The congenital microcephaly and insulin-dependent
diabetes can be explained by the presence of abnormalThe Americlevels of neuronal apoptosis in brain and pancreas speci-
mens from the sibling of index patient 2. In this brain,
there is additional evidence for insufficient myelination,
which suggests either that early common progenitors of
both neural and glia lineage are depleted or that matura-
tion of the oligodendrocyte progenitors is blocked. Consis-
tent with the hypothesis of progenitor depletion and block
in maturation, the pattern of Ier3ip1 in the mouse brain at
E14.5 shows selective expression at the proliferative
ventricular and subventricular zone, where the common
neuro-glial progenitors are located before differentiation
into separate lineages. Although naturally occurring cell
death represents a final pathogenic mechanism of many
disorders, apoptosis is an essential and impressive feature
of cortical brain development. During neurogenesis, about
70% of progenitor cells in the ventricular and subventricu-
lar zone undergo apoptosis, this number being similar to
that of postmitotic cells, leading to the suggestion that
apoptosis controls stem cell population.35 Abnormal
increase of apoptosis in the patients with IER3IP1 muta-
tion could be the result of either insufficient regulation
of mitosis and differentiation of neural progenitors or
insufficient protection from proapoptotic stimuli. Distinc-
tion between these two mechanisms might be particularly
important for the identification of proapoptotic stimuli
extrinsic to the cell metabolism, such as oxidative stress,
which might be preventable.36 Fibroblasts from an indi-
vidual with an IER3IP1 mutation show increased rates of
apoptotic cell death when exposed to DTT. Additionally,
silencing of IER3IP1 leads to an increase in the apoptosis
rate in control fibroblasts after DTT treatment. On the
one hand, these results link the effect of the mutation
with the onset of apoptosis, but on the other hand, they
suggest that IER3IP1 intervenes under ‘‘stress’’ stimuli.
IER3IP1 is putatively involved in cell differentiation and
cell death processes, under regulation of transcription
factors TNF-a and Sp1.34 If IER3IP1 normally protects the
cell from stimuli inducing apoptosis, the modest, albeit
significant, response to TNF-a places human IER3IP1 in
the ‘‘death receptors’’ cascade.37 IER3IP1 also has a reported
role in ceramide apoptosis in neurons.38
IER3IP1 is a highly conserved protein that is found in
humans, mice, zebrafish (Figure 4A), and yeast (homolog
to Yos1p) and is highly expressed in the developing
cortex and in the beta cells of the pancreas. IER3IP1
putatively interacts with IER3 and, on the basis of its
sequence homology to the yeast protein Yos1p and
preliminary experimental evidence, is an ER protein con-
taining at least one transmembrane domain andmediating
vesicular transport between Golgi and ER.33 However, it
also contains a G-patched domain present in RNA-associ-
ated proteins.
IER3IP1 has a similarity in name to and may interact
directly with IER3, although there is no available experi-
mental evidence published to prove this. IER3 is a highly
conserved protein consisting of 156 amino acids in
humans and consists of a putative transmembrane domainan Journal of Human Genetics 89, 265–276, August 12, 2011 273
and a nuclear localization site. IER3 is described as having
both a pro- and an antiapoptotic role.39,40
An elevated expression of IER3 in hepatocytes and
pancreatic tumor cell lines triggers apoptosis in response
to various apoptotic stimuli. IER3 has also been reported
to be part of the DNA damage-induced and p53-mediated
apoptosis in rodent and human cells.40
Our experiments showing increased expression of IER3
and IER3IP1 after induction with TNF-a could provide
clues that IER3IP1 regulates apoptosis via interaction
with IER3, either through cooperation or through interfer-
ence with IER3 function.
We therefore conclude that IER3IP1 is an important
gene, involved in the development of microcephaly and
diabetes via dysregulation of apoptosis.
The role of IER3IP1 in cortical development and
pathogenesis of epilepsy and diabetes is obscure, but it
seems essential from the early stages of development,
such as the period of neural progenitor proliferation. It
is unknown when diabetes begins in patients because
there has been no way to test it prenatally, but the presence
of microcephaly with simplified gyration indicates a
crucial role already existing during gestation. Severe infan-
tile epileptic encephalopathy is very unusual in primary
microcephaly and has been reported only in patients
with WDR62 mutations.41 In these patients, however,
the structure of the cortex is deeply abnormal and shows
both migration and organization defects, both high risk
factors for epilepsy. The rare combination of primary
microcephaly with severe infantile epilepsy has been
observed in PNKP mutations.42 In this disorder, seizures
and microcephaly are not related to degenerative changes,
but to probable defects in DNA-repair mechanisms of
nucleotide excision or single- or double-stranded breaks.
Interestingly, mouse neuronal cells show increased
apoptosis rates when PNKP is silenced by siRNA.
Apoptosis, or programmed cell death, is also the end
point of the unfolded protein response.WRS, which shows
phenotypic similarity to our patients’ syndrome, is caused
by a mutation in EIF2AK3, which encodes a kinase in the
ER membrane, one of four that phosphorylates EIF2a
(also known as Perk in mice), having an important role
in the unfolded protein response.15 When a protein is
misfolded, EIF2a is phosphorylated, resulting in lower
levels of translation initiation of the protein and eventu-
ally prevention from apoptosis. This is proven by the
Perk knockout mice, which have an increased rate of
apoptosis and destruction of beta cells causing a phenotype
similar to WRS in humans.43 It is interesting that both of
the IER3IP1 mutations found are in the putative hydro-
phobic regions, which therefore seem to be very function-
ally relevant. It is possible that the role of IER3IP1 in
protection from apoptosis is also played by regulating
and/or preventing nascent protein (mis)folding in the ER
membrane at the lumen and thus preventing activation
of the UPR response. This and other questions might be
addressed by future protein studies on subcellular localiza-274 The American Journal of Human Genetics 89, 265–276, August 1tion and on identification of interacting partners. These
studies will also be instrumental in the understanding of
severe infantile epilepsy and infantile diabetes.
Supplemental Data
Supplemental Data include five figures and three tables and can be
found with this article online at http://www.cell.com/AJHG/.
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